Anwendungsgebiet
Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Matever is indicated as adjunctive therapy: in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.